Huh G, Ryu JK, Chun JW, et al. - Researchers assessed how systemic inflammatory response markers could impact the survival outcomes of patients suffering from unresectable intrahepatic cholangiocarcinoma (IHC). They performed a retrospective review of cases with histologically verified, unresectable IHC managed with gemcitabine plus cisplatin (GP) chemotherapy in a single tertiary hospital from 2012 to 2016. In all participants, the median progression-free survival (PFS) and overall survival (OS) were found to be 7.8 months and 9.9 months, respectively. A short PFS was shown to be related to high platelet-to-lymphocyte ratio (PLR) and distant lymph node metastasis in multivariable cox-regression analysis. Overall, in patients with unresectable IHC undergoing GP chemotherapy, high PLR was identified as an independent prognostic factor of a short PFS and OS.